Ashling Wahner

Read a recap of the episodes of OncLive On Air that aired in March 2025.

D-VRd with daratumumab/lenalidomide maintenance led to sustained PFS and MRD negativity across high-risk subgroups of newly diagnosed multiple myeloma.

A comparative analysis showed that apraglutide plus ruxolitinib improved response rates vs ruxolitinib monotherapy in steroid-refractory GI aGVHD.

Nataliya Uboha, MD, PhD, discusses the benefits of expanding the first-line ESCC treatment paradigm with tislelizumab plus chemotherapy.

Steven Devine, MD; Everett Meyer, MD, PhD; and Sophie Paczesny, MD, PhD, discuss their most highly anticipated presentations from the 2025 EBMT Meeting.

The investigational new drug application for the RDC SKB107 for the management of solid tumor bone metastases has been approved in China.

Olalekan O. Oluwole, MD, discusses research findings showing that patients with LBCL may not need prolonged hospital monitoring following axi-cel infusion.

A real-world study showed OS outcomes with eribulin similar to those with trabectedin in doxorubicin-pretreated patients with advanced liposarcoma.

The combination of toripalimab and bevacizumab has been approved in China for the treatment of patients with unresectable or metastatic HCC.

R. Lor Randall, MD, FACS, discusses the development of a bone marrow matrix to study osteosarcoma and the model’s mechanisms of metastasis control.

China’s NMPA has granted conditional approval to the EZH2 inhibitor tazemetostat for patients with relapsed/refractory EZH2-mutated follicular lymphoma.

Tsewang Tashi, MD, discusses the efficacy and tolerability of targeted therapies like avapritinib for patients with indolent systemic mastocytosis.

Second-line fruquintinib plus sintilimab improved PFS, ORR, and DOR outcomes vs everolimus or axitinib monotherapy in advanced/metastatic RCC.

David M. Swoboda, MD, discusses data with quizartinib in FLT3-negative AML from the QUIWI trial and the rationale for the QuANTUM-Wild trial.

Dostarlimab plus chemotherapy improved 24-month DOR rates vs placebo plus chemotherapy in patients with primary advanced or recurrent endometrial cancer.

BVAC-C was effective with a manageable safety profile when combined with durvalumab in patients with recurrent HPV-positive cervical cancer.

Treatment with pembrolizumab monotherapy was effective and well tolerated in pretreated patients with advanced clear cell gynecologic cancers.

A BLA has been accepted in China seeking the approval of tisotumab vedotin for metastatic cervical cancer that has progressed on or after systemic therapy.

The feasibility and safety of treatment with SAR443216 support the further investigation of this agent in patients with advanced HER2-positive tumors.

Neratinib-containing combinations are consistently effective across CNS end points in patients with HER2-positive breast cancer brain metastases.

Benefits were seen with abemaciclib/fulvestrant regardless of metastatic site in HER2-negative advanced breast cancer following prior CDK4/6 inhibition.

Treatment with sacituzumab govitecan was effective and tolerable in real-world patients with mTNBC who received the agent in later-line settings.

Treatment with liso-cel induced long-term CR/CRi rates and high uMRD rates in patients with CLL/SLL following progression on BTK inhibition and venetoclax.

Treatment with 177Lu-edotreotide significantly improved PFS and numerically increased OS vs SOC everolimus in grade 1 or 2 SSTR-positive GEP-NETs.

R. Lor Randall, MD, FACS, discusses the significance of the FDA approval of vimseltinib for patients with symptomatic TGCT.

Aditya Bardia, MD, MPH, FASCO, discusses how the FDA approval of T-DXd for HER2-low/-ultralow metastatic breast cancer has affected the treatment paradigm.

Katy Beckermann, MD, PhD, discusses key findings from a PRO analysis of tivozanib/nivolumab vs tivozanib alone in ICI-pretreated RCC.

The FDA has approved tislelizumab-jsgr plus chemotherapy for frontline use in adult patients with advanced esophageal squamous cell carcinoma and PD-L1 expression.

Regina Barragan-Carrillo, MD, discusses a study of RCC clinical trial availability and barriers to opening RCC clinical trials in lower-income countries.

Read a recap of the episodes of OncLive On Air that aired in February 2025.